Pfizer cuts jobs at its Michigan plant
This article was originally published in Scrip
Pfizeris cutting 275 jobs at its biggest manufacturing plant in Kalamazoo, Michigan. The reductions, which will begin next month, will affect supervisory and support staff as well as some operational staff, such as project engineers. The Kalamazoo plant makes sterile injectable drugs, liquid medications, ointments and active ingredients for pills, including the antibiotic Zyvox (linezolid) and the birth control injection Depo-Provera (medroxyprogesterone acetate injectable suspension). The reductions are part of Pfizer's global restructuring plan in which the company hopes to reduce its workforce by 10,000 and reduce its costs by $1.5 billion to $2 billion by the end of this year.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.